Peter Hofland, PhD's Blog Posts Tagged 'Clinical' (15)

Search Blog Posts

Human Mesenchymal Stem Cell Impact the Clinical Use for Prevention and Treatment of Graft-versus-host Disease

Mesenchymal stem cells (MSCs) effectively treat graft-versus-host disease (GvHD) while not interfering with bone marrow transplant’s efficacy in treating leukemia.



Jeffery J. Auletta, MD, Kenneth Cooke, MD, and colleagues at the Pediatric Blood and Marrow Transplant Program, Rainbow Babies and Children's Hospital, Cleveland, OH and the National Center for Regenerative Medicine, Cleveland, OH, presented this significant finding that as part of a poster…

Continue

Added by Peter Hofland, PhD on December 10, 2011 at 7:00pm — No Comments

Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer Treated with NKTR-102

Results from a Phase II clinical study evaluating single-agent NKTR-102 (Nektar Therapeutics) as a second- and third-line treatment in patients with metastatic breast cancer demonstrates sustained clinical benefit in 46% of them. The results of the study were presented today at the 47th annual meeting of the American Society of Clinical Oncology Meeting (ASCO).… Continue

Added by Peter Hofland, PhD on June 4, 2011 at 12:00pm — No Comments

Personalized Medicine Feasible and May Improves Outcomes

A major personalized medicine initiative at The University of Texas’ M.D. Anderson Cancer Center found that matching patients with advanced cancer in Phase I clinical trials with targeted drugs on the basis of the molecular profiles of the patients’ tumors resulted in higher response rates and longer survival and time to treatment failure (TTF) compared to treating patients without molecular matching.… Continue

Added by Peter Hofland, PhD on June 3, 2011 at 1:00pm — No Comments

New Opinion on EGFR Mutation Testing to Identify NSCLC Patients Benefitting From Targeted Agents

The American Society of Clinical Oncology (ASCO) today issued a provisional clinical opinion (PCO) on the clinical use of epidermal growth factor receptor (EGFR) mutation testing to identify patients with advanced lung cancer who may benefit from targeted agents known as EGFR tyrosine kinase inhibitors. These treatments include gefitinib (Iressa®, AstraZeneca) and erlotinib (… Continue

Added by Peter Hofland, PhD on April 11, 2011 at 3:00pm — No Comments

New Clinical Practice Guideline on the Role of Bone-Modifying Agents in the Prevention and Treatment of Bone Metastases in Patients with Metastatic Breast Cancer

The American Society of Clinical Oncology (ASCO), the world’s leading professional organization representing physicians who care for people with cancer, today issued an update to its clinical practice guideline on the use of bone-modifying agents, in particular, osteoclast inhibitors, to prevent and treat skeletal complications from bone metastases in patients with metastatic breast cancer.



The new guideline… Continue

Added by Peter Hofland, PhD on February 22, 2011 at 4:00pm — No Comments

Azacitidine Receives Positive Final Appraisal from U.K. National Institute for Health and Clinical Excellence for Use in the National Health Service (NHS) in England and Wales

In a statement issued today the National Institute for Health and Clinical Excellence (NICE) released a Final Appraisal Determination (FAD) recommending azacitidine (Vidaza®, Celgene International Sàrl), within its licensed indication, as an option for the treatment of patients in England and Wales with myelodysplastic syndromes (MDS) and acute myeloid leukaemia.… Continue

Added by Peter Hofland, PhD on February 16, 2011 at 5:00pm — No Comments

Phase II Clinical Trial for Biosimilar Version of Leading Monoclonal Antibody Rituximab Reinforces Sandoz's Commitment to Maintain Global Market Leadership

Sandoz, the generic pharmaceuticals division of Novartis, announced today that it has begun a phase II clinical trial in patients for biosimilar rituximab (Rituxan® / Mabthera®, Roche/Genentech), a leading monoclonal antibody indicated in conditions including… Continue

Added by Peter Hofland, PhD on January 10, 2011 at 7:30am — No Comments

Lenalidomide Either with Rituximab or Following Rituximab Combination Shows Promise for Patients Treated for Chronic Lymphocytic Leukemia (CLL)

A Study evaluating lenalidomide (Revlimid®, Celgene International Sàrl), an oral immunomodulatory drug or IMiD [1], as consolidation therapy in patients with previously untreated chronic lymphocytic leukemia (CLL) reported that 91% of patients were still alive after a median follow-up of 21 Months. A Second study evaluating a combination of lenalidomide and rituximab (Rituxan®, Genentech, Inc/Roche Group), a monoclonal antibody, in Patients with relapsed/refractory CLL reported…

Continue

Added by Peter Hofland, PhD on December 4, 2010 at 11:00am — No Comments

Industry Funded Clinical Drug Trials Are More Likely to Publish Favorable Results; Researchers Call For More Disclosure To Reduce Possibility Of Bias

When published results are systematically tracked for drug trials registered with ClinicalTrials.gov, those from industry-funded trials are the likeliest to be favourable to the drug in question, report researchers in the August 3, 2010 issue of the Annals of Internal Medicine.



The authors of the article reviewed 546 drug trials conducted between 2000 and 2006 and listed with… Continue

Added by Peter Hofland, PhD on November 29, 2010 at 4:30pm — No Comments

National Institutes of Health (NIH) Awards Nearly $3 Million For Ground-Breaking Immunotherapy Clinical Study

Scientists at the Barbara Ann Karmanos Cancer Institute in Detroit, USA, have received a nearly $3 million, five-year research project (RO1) grant from the National Institutes of Health to study a potentially ground-breaking immunotherapy treatment for women with one of the deadliest forms of breast cancer – triple-negative breast cancer. The research is exclusive to the… Continue

Added by Peter Hofland, PhD on October 18, 2010 at 2:00pm — No Comments

Combination Therapy Doubles Overall Response Rate in Colorectal Cancer Clinical Trial

A combination of the new drug candidate Imprime PGG® (Biothera) and cetuximab (Erbitux®, ImClone/Bristol-Myers Squibb and Merck KGaA ) doubled the overall response rates for second- and third-line metastatic colorectal cancer patients participating in a Phase Ib/IIa clinical trial. The completed trial results were released at the 35th European Society for Medical Oncology (ESMO) Congress in Milan, Italy (October 8 - 12,… Continue

Added by Peter Hofland, PhD on October 12, 2010 at 12:30pm — No Comments

Perspectives of Both Clinicians and Patients Provide a More Complete Picture of Negative Impact of Cancer Treatment

In clinical trials for cancer, it is standard for clinicians rather than patients to report adverse symptom side effects from treatments, such as nausea and fatigue. At present, patient self-reporting, although important, is not a well studied source of this information. A new longitudinal study from researchers at Memorial Sloan-Kettering Cancer Center finds that while… Continue

Added by Peter Hofland, PhD on November 16, 2009 at 7:00pm — No Comments

Anemic Patients With Myelodysplastic Syndromes Gain Long-Term Benefits From Erythropoietin and Myeloid Growth Factor Hormones

Myelodysplastic Syndromes (MDS), a group of blood disorders that can lead to acute myeloid leukemia (AML) in some patients, often cause severe anemia (when the body lacks a sufficient number of functional red blood cells). While certain treatments can help manage the symptoms of anemia, some studies have suggested that they may lead to complications.



Now a new study demonstrates that MDS patients with anemia may benefit from treatment with an erythropoietin (EPO)-based… Continue

Added by Peter Hofland, PhD on September 17, 2009 at 10:24pm — No Comments

Standard of Care for Anal Cancer Should Not Be Changed

Findings from the largest trial ever conducted for anal cancer have shown that the current standard of care, using a novel, continuous radiation therapy delivery program combined with 5-fluorouracil (5-FU), a drug commonly used to treat many types of cancer including, breast, head and neck, anal, stomach, colon and some skin cancers, and mitomycin-C (a chemotherapy drug mainly used to treat bladder and rectal cancers, but also sometimes pancreatic, lung and breast cancers), results in the… Continue

Added by Peter Hofland, PhD on May 30, 2009 at 5:00pm — No Comments

Photodynamic Therapy Shows Efficacy in Head and Neck Cancers

Temoporfin-mediated photodynamic therapy represents a major advance in the treatment of head and neck cancer, yielding complete response rates comparable with those published for surgery or radiotherapy, according to phase II data reported here last week during ECCO 11, the European Cancer Conference.

Temoporfin-mediated photodynamic therapy (Foscan PDT) is an "effective and well-tolerated treatment" and can be administered without surgery, said Dr. Colin Hopper, a consultant…

Continue

Added by Peter Hofland, PhD on November 1, 2001 at 4:00pm — No Comments

Latest Blog Posts

Most Popular Blog Posts

Monthly Archives

2013

2012

2011

2010

2009

2008

2007

2005

2004

2001

ADVERTISEMENT

Onco'Zine is present here

Bookmark / Share

Join the Conversation!

Pharmceutical Business News


© 2013   Created by Peter Hofland, PhD.

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+